Several preclinical studies have demonstrated that OVVs encoding PD-1/PD-L1 blocking agents can potentiate anti-tumor immunity, particularly in immunologically “cold” tumors such as hepatocellular carcinoma. Here, PDCD1 is linked to hepatocellular carcinoma.